UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P O Box 1450 Alexandria, Virgima 22313-1450 www.uspto.gov

### NOTICE OF ALLOWANCE AND FEE(S) DUE

20462 7590 01/03/2011

GlaxoSmithKline GLOBAL PATENTS -US, UW2220 P. O. BOX 1539 EXAMINER QAZI, SABIHA NAIM

PAPER NUMBER

ART UNIT

KING OF PRUSSIA, PA 19406-0939 DATE MAILED: 01/03/2011

 APPLICATION NO.
 FILING DATE
 FIRST NAMED INVENTOR
 ATTORNIY DOCKET NO.
 CONFIRMATION NO.

 10/561,498
 12/19/2005
 John Liddle
 PB60330
 6334

TITLE OF INVENTION: SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCIN ANTAGONISTS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1510	\$300	\$0	\$1810	04/04/2011

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

#### HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and I/2 the ISSUE FIEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

#### PART B - FEE(S) TRANSMITTAL

# Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where

indicated unless corrects maintenance fee notifica	ed below or directed oth tions.	ng the Patent, advance onerwise in Block 1, by (	a) specifying a new co	rrespor	ndence address;	and/o	(b) indicating a sepa	rate "FEE ADDRESS"	for
		ock 1 for any change of address)	I I	ree(s)	Transmittal. Thi	s certil	icate cannot be used f	r domestic mailings of or any other accompany nt or formal drawing, r	ving
20462	7590 01/03	/2011			Cer	tificate	of Mailing or Trans	mission	
P. O. BOX 1539	ENTS -US, UW222		I S a t	hereb states f iddress ransmi	y certify that the Postal Service we led to the Mail litted to the USP	is Fee( rith sul Stop FO (57	s) Transmittal is being ficient postage for firs ISSUE FEE address I) 273-2885, on the d	deposited with the Un t class mail in an envel above, or being facsin ate indicated below.	ited lope mile
KING OF PRUS	SSIA, PA 19406-09:	39	ſ					(Depositor's ne	ıme)
			Ī					(Signat	ure)
			[					(I	Date)
APPLICATION NO.	FILING DATE		FIRST NAMED INVENT	OR		ATTO	RNEY DOCKET NO.	CONFIRMATION NO.	_
10/561,498	12/19/2005		John Liddle			PB60330		6334	
TITLE OF INVENTION	: SUBSTITUTED DIKE	TOPIPERAZINES AND	THEIR USE AS OXY	TOCIN	N ANTAGONIS	TS			
APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DU	E P	REV. PAID ISSUI	FEE	TOTAL FEE(S) DUE	DATE DUE	
nonprovisional	NO	\$1510	\$300	_	\$0		\$1810	04/04/2011	
EXAM	IINER	ART UNIT	CLASS-SUBCLASS						
QAZI, SAB		1628	514-235500						
1. Change of correspondence address or indication of "Fee Address" (3 CFR 1.363).  Change of correspondence address (or Change of Correspondence Address form PTO/SBI 1/22) attached.  The Address' indication for "Fee Address" indication form PTO/SBI 4/7; Rev 03-02 c more recent) attached. Use of a Custom Number is required.			(I) the names of up or agents OR, altern (2) the name of a si	e of a single firm (having as a member a  ttorney or agent) and the names of up to patent attorneys or agents. If no name is					
(A) NAME OF ASSI	less an assignee is ident h in 37 CFR 3.11. Comp GNEE	ified below, no assignee pletion of this form is NO	data will appear on th T a substitute for filing (B) RESIDENCE: (CI	e pater an assi ITY an	d STATE OR C	OUNT	'RY)		
Please check the appropr	iate assignee category or	categories (will not be p	rinted on the patent):	□ Inc	dividual 🖵 Co	rporati	on or other private gro	up entity Governn	ient
4a. The following fee(s)  Issue Fee	are submitted:	4	b. Payment of Fee(s): (I		first reapply ar	y pre	lously paid issue fee	shown above)	
	vo small entity discount p	permitted)	A check is enclose Payment by credit		Form PTO-2038	is atta	ched.		
Advance Order -			The Director is her overpayment, to D	eby au	thorized to char Account Number	ge the	required fee(s), any de (enclose a	ficiency, or credit any n extra copy of this form	n).
5. Change in Entity Sta	tus (from status indicates		☐ b. Applicant is no						_
NOTE: The Issue Fee an interest as shown by the									y ir
Authorized Signature		Tuo Tuo Tuo Tuo	· one						_
Typed or printed name			Registration No.						
This collection of inform an application. Confiden submitting the completes this form and/or suggesti Box 1450, Alexandria, V Alexandria, Virginia 223	nation is required by 37 C tiality is governed by 35 d application form to the ions for reducing this but 'irginia 22313-1450. DC	CFR 1.311. The information U.S.C. 122 and 37 CFR USPTO. Time will vary rden, should be sent to the D NOT SEND FEES OR	on is required to obtain 1.14. This collection is depending upon the in the Chief Information Of COMPLETED FORMS	or retai estima dividu ficer, U	-		tic which is to file (and to complete, including s on the amount of tin ark Office, U.S. Depa D TO: Commissioner	by the USPTO to proc g gathering, preparing, ne you require to comp utment of Commerce, I for Patents, P.O. Box 1-	ess) and dete P.O. 450,

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



### UNITED STATES PATENT AND TRADEMARK OFFICE

#### UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P O Box 1450 Alexandria, Virgima 22313-1450 www.uspto.gov

APPLICATION NO		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/561,498	12/19/2005		John Liddle	PB60330	6334	
20462	7590	01/03/2011		EXAM	UNER	
GlaxoSmithKline				QAZI, SABIHA NAIM		
GLOBAL PATENTS -US, UW2220				ART UNIT	PAPER NUMBER	
P. O. BOX 1539 KING OF PRUSSIA, PA 19406-0939			1628 DATE MAII ED: 01/03/201	1		

## Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 583 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 583 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

#### Application No. Applicant(s) 10/561.498 LIDDLE, JOHN Notice of Allowability Examiner Art Unit Sahiha Qazi 1628 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTQL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFB 1.313 and MPEP 1308. This communication is responsive to 9/13/10. The allowed claim(s) is/are 4 and 10. 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). b) \( \sum \) Some\* c) \( \sum \) None of the: 1. A Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). \* Certified copies not received: \_\_\_\_\_. Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) Including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) I including changes required by the attached Examiner's Amendment / Comment or in the Office action of Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1. | Notice of References Cited (PTO-892) 5. Notice of Informal Patent Application 2. Notice of Draftperson's Patent Drawing Review (PTO-948) Interview Summary (PTO-413). Paper No./Mail Date 3. Information Disclosure Statements (PTO/SB/08), 7. T Examiner's Amendment/Comment Paper No./Mail Date 4. T Examiner's Comment Regarding Requirement for Deposit 8. T Examiner's Statement of Reasons for Allowance of Biological Material

/Sabiha Qazi/

Primary Examiner, Art Unit 1628

9. 

☐ Other